Mainz Biomed N.V.

NasdaqCM:MYNZ Stock Report

Market Cap: US$2.9m

Mainz Biomed Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MYNZ?
Owner TypeNumber of SharesOwnership Percentage
Institutions28,0164.38%
Individual Insiders87,42913.7%
General Public524,21982%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.7%.

Top Shareholders

Top 25 shareholders own 18.05% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.4%
Moritz Eidens
28,159US$127.8k0%no data
3.63%
KfW, Asset Management Arm
23,203US$105.3k-25%no data
2.94%
Guido Baechler
18,809US$85.4k0%no data
2.8%
Hans Hekland
17,922US$81.4k0%no data
1.41%
Philipp Freese
9,049US$41.1k0%no data
0.83%
William Caragol
5,317US$24.1k0%no data
0.45%
Darin Leigh
2,885US$13.1k0%no data
0.34%
Heinrich Dreismann
2,200US$10.0k0%no data
0.18%
Vontobel Asset Management, Inc.
1,125US$5.1k80%no data
0.14%
Gregory Tibbitts
875US$4.0k0%no data
0.14%
Nicole Holden
875US$4.0k0%no data
0.14%
Alberto Libanori
875US$4.0k0%no data
0.12%
Northern Trust Global Investments
748US$3.4k0%no data
0.11%
Steward Partners Investment Advisory, LLC
725US$3.3k0%no data
0.092%
Two Sigma Securities, LLC, Asset Management Arm
587US$2.7k0%no data
0.059%
Geode Capital Management, LLC
379US$1.7k0%no data
0.057%
Jane Street Group, LLC, Asset Management Arm
363US$1.6k0%no data
0.047%
XTX Holdings Limited, Asset Management Arm
298US$1.4k5.3%no data
0.046%
Frank Krieg-Schneider
294US$1.3k0%no data
0.042%
Greenwich Investment Management, Inc.
271US$1.2k0%no data
0.039%
Wealth Quarterback LLC
250US$1.1k0%no data
0.026%
Christopher Von Torne
169US$767.30%no data
0.0072%
Strategic Advisers LLC
46US$208.80%no data
0.0025%
Citigroup Inc.,Banking and Securities Investments
16US$72.60%no data
0.00078%
Morgan Stanley, Investment Banking and Brokerage Investments
5US$22.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 20:44
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mainz Biomed N.V. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi ChenH.C. Wainwright & Co.